Biomarkers in Pulmonary Arterial Hypertension Treated With Nilotinib

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by (Responsible Party):
Kewal Asosingh, Ph.D, The Cleveland Clinic
ClinicalTrials.gov Identifier:
NCT01320865
First received: March 18, 2011
Last updated: February 3, 2014
Last verified: February 2014
  Purpose

The investigators hypothesize that bone marrow progenitor cells are mobilized into the circulation in PAH, home to the lungs and differentiate into mast cells, which promote vascular remodeling and vasoconstriction through release of renin and chymase. As a corollary to this, the investigators hypothesize that anti cKit tyrosine kinase inhibitor (TKI), nilotinib, provides clinical benefit to patients through inhibition of mast cell progenitor proliferation, mobilization and differentiation. To test this, the investigators will determine if mast cell progenitors and mast cell biomarkers are related to nilotinib clinical response. This will be an ancillary study, part of a placebo-controlled, double-blind multi center clinical trial of nilotinib in pulmonary arterial hypertension.


Condition
PAH

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by The Cleveland Clinic:

Primary Outcome Measures:
  • Measuring circulating markers of Nilotinib affect [ Time Frame: within one year of the end of the study ] [ Designated as safety issue: No ]
    We will measure markers of mast cell activation in blood and urine before and during treatment with nilotinib.


Secondary Outcome Measures:
  • Evaluate effect of Nilotinib on the activation of mast cells. [ Time Frame: within one year of the end of the study ] [ Designated as safety issue: No ]
    We will measure markers of mast cell activation in blood and urine before and during treatment with nilotinib. We will also look at the proliferation of mast cell progenitors and correlate this to clinical markers used to monitor this disease.


Enrollment: 0
Study Start Date: August 2010
Study Completion Date: December 2012
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
Subjects with PAH treated with nilotinib

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients diagnosed with PAH that are enrolled in the Nilotinib clinical trial. http://clinicaltrials.gov/ct2/show/NCT01179737?term=tasigna+and+pulmonary+hypertension&rank=1

Criteria

Inclusion Criteria:

This study is a substudy and subjects must be enrolled in the main trial:

See Study Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH) In clinical trials. (clinical Trial ID NCT01179737)

http://clinicaltrials.gov/ct2/show/NCT01179737?

Exclusion Criteria:

Subjects are not enrolled in the main study:

See Study Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH) In clinical trials. (clinical Trial ID NCT01179737)

http://clinicaltrials.gov/ct2/show/NCT01179737?term=tasigna+and+pulmonary+hypertension&rank=1

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01320865

Locations
United States, Ohio
Cleveland Clinic
Cleveland, Ohio, United States, 44195
Sponsors and Collaborators
The Cleveland Clinic
Investigators
Principal Investigator: Kewal Asosingh, Ph.D The Cleveland Clinic
  More Information

Additional Information:
Publications:
Responsible Party: Kewal Asosingh, Ph.D, Associate Staff, The Cleveland Clinic
ClinicalTrials.gov Identifier: NCT01320865     History of Changes
Other Study ID Numbers: Novartis AMN-107
Study First Received: March 18, 2011
Last Updated: February 3, 2014
Health Authority: United States: Institutional Review Board

ClinicalTrials.gov processed this record on July 26, 2014